Discovery and Development of Novel Ret Inhibitors for the Treatment of Pervasive Malignancies
Targeted cancer therapeutics represent the advent of a new therapeutic age, brought forth by the small molecule tyrosine kinase inhibitor (TKI) imatinib (Gleevec®). Imatinib is able to cause complete and sustained remissions in patients with chronic myelogenous leukemia (CML) driven by the Abelson...
Main Author: | Frett, Brendan |
---|---|
Other Authors: | Li, Hong-yu |
Language: | en_US |
Published: |
The University of Arizona.
2014
|
Subjects: | |
Online Access: | http://hdl.handle.net/10150/325495 |
Similar Items
-
DISCOVERY AND BIOPHYSICAL CHARACTERIZATION OF ALLOSTERIC INHIBITORS OF FACTOR XIa (FXIa)
by: Argade, Malaika
Published: (2012) -
Development of Novel Phenanthroline and Thiazole Orange Derived G-quadruplex Ligands and Telomerase Inhibitors
by: Wang, Siwen
Published: (2018) -
THE DEVELOPMENT OF NOVEL NON-PEPTIDE PROTEASOME INHIBITORS FOR THE TREATMENT OF SOLID TUMORS
by: Miller, Zachary C.
Published: (2018) -
Design and delivery of selective inhibitors of tumor overexpressed isozymes of carbonic anhydrase- towards new theranostic systems for cancer detection and treatment
by: AKOCAK, SULEYMAN
Published: (2014) -
COMPUTATIONAL MODELING GUIDED DISCOVERY OF NOVEL INHIBITORS OF MPGES-1 AND BUTYRYLCHOLINESTERASE AS DRUG CANDIDATES
by: Zhou, Shuo
Published: (2019)